1027074-21-0

Upstream product

• 79-03-8 propionyl chloride 
• 51436-99-8 2-fluoro-4-bromotoluene 
• 76283-09-5 4-bromo-2-fluorobenzyl bromide 
• 1025808-14-3 4'-[4-Ethyl-5-(1-hydroxy-allyl)-2-propyl-imidazol-1-ylmethyl]-3'-fluoro-biphenyl-2-sulfonic acid tert-butylamide 
• 169203-66-1 1-<<2'-<(tert-butylamino)sulfonyl>-3-fluoro(1,1'-biphenyl)-4-yl>methyl>-4-ethyl-5-propenoyl-2-propyl-1H-imidazole 
• 169203-65-0 1-<<2'-<(tert-butylamino)sulfonyl>-3-fluoro(1,1'-biphenyl)-4-yl>methyl>-4-ethyl-5-formyl-2-propyl-1H-imidazole 
• 169203-64-9 1-(4-bromo-2-fluorobenzyl)-4-ethyl-5-formyl-2-propyl-1H-imidazole 

Downstream Products

• 1027402-86-3 N-{3-[5-Ethyl-3-(3-fluoro-2'-sulfamoyl-biphenyl-4-ylmethyl)-2-propyl-3H-imidazol-4-yl]-3-oxo-propyl}-N-pyridin-3-yl-propionamide 

Relevant academic research and scientific papers

Balanced AT1/AT2 receptor antagonists. 4. XR510 and related 5-(3- amidopropanoyl)imidazoles possessing equal affinity for the AT1 and AT2 receptors

The identification of the AT1 and AT2 receptor subtypes has stimulated interest in developing balanced angiotensin II receptor antagonists. A series of 5-(3-amidopropanoyl)imidazoles has been prepared which possess balanced affinity for the AT1 and AT2 receptors. XR510 (1), 1-[[2'- [[(isopentoxycarbonyl)amino]sulfonyl]-3-fluoro(1,1'-biphenyl)-4-yl]methyl]- 5-[3-(N-pyridin-3-ylbutanamido)propanoyl]-4-ethyl-2-propyl-1H-imidazole, potassium salt, exhibits subnanomolar affinity for both receptor sites. XR510 is very active in lowering blood pressure in renal hypertensive rats and furosemide-treated dogs following oral administration.